Latest Administration News

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Australian Unity Limited reported increased revenue for the half-year ending December 2025, but earnings declined sharply due to inflationary pressures and ongoing transformation investments. The company also completed a leadership transition and strengthened its balance sheet.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Suncorp Group Limited has updated its dividend distribution details, confirming a fully franked ordinary dividend of AUD 0.17 per share payable in March 2026, with tailored currency payment options for shareholders.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Dominion Income Trust 1 has reported a robust $12.3 million profit and paid distributions totaling 359.41 cents per unit in its inaugural half-year ending December 2025. The Trust outperformed its benchmark, signalling a promising start for investors.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.

Elevra Lithium Limited reported an 8% revenue increase and a US$74 million profit for the first half of FY26, driven by higher lithium prices and strategic merger synergies. The company advances its North American Lithium expansion while managing temporary production challenges.

Kali Metals has acquired SQM Australia’s 30% stake in the DOM’s Hill and Pear Creek projects, consolidating its Pilbara portfolio and setting the stage for renewed gold and base metals exploration.

SIV Capital Limited reported a 29.7% increase in its half-year loss to $172,763, with revenue down 41%, while its ASX suspension continues as it pursues a confidential transaction to regain listing status.